April 19th 2024
Your daily dose of the clinical news you may have missed.
April 17th 2024
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
April 11th 2024
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
March 7th 2024
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
February 29th 2024
Daily Dose: RSV Infection in Infancy & Risk of Asthma in Childhood
Your daily dose of clinical news you may have missed.
RSV Infection During Infancy Linked to Higher Risk of Asthma in Childhood
Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.
6 Biologics for Severe Asthma, 3 Essential Facts on Each
For each of the 6 biologic agents FDA-approved for severe asthma, find the mechanism of action, indication, and biomarkers that predict enhanced response.
Daily Dose: Pediatric Asthma Risk Score
Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization
AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.
AAAAI 2023: Pediatric Asthma Risk Score Validated in Multi-cohort Study
Future studies may consider PARS the new gold standard in predicting pediatric asthma risk, said study authors.
For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up
AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.
Endotypes of Severe Asthma: 5 Questions on Pathways, Biomarkers, Biologics
Check your knowledge of mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment.
Tezepelumab FDA-approved for Self-administration by Patients with Severe Asthma
The approval offers patients the choice to administer the monoclonal antibody at home using a prefilled device or to continue to receive it in a clinical setting.
6 Questions on Severe Uncontrolled Asthma: Key Characteristics for Primary Care
Severe uncontrolled asthma is a clinical treatment challenge even with advanced biologic therapies available. Test your knowledge of a few key characteristics with a quick quiz.
Air Pollution Independently Linked to Asthma Exacerbation in Urban-dwelling Children
Asthma exacerbations in children living in low-income urban areas were significantly associated with reduced air quality and specific pollutants in a new analysis.
Tezepelumab Reduced Exacerbations in Severe, Uncontrolled Asthma, Regardless of Number of Additional Controller Medications
CHEST 2022. Tezepelumab significantly reduced AAER and improved lung function in patients taking 1, 2, or ≥3 long-acting β-agonists in addition to ICS.
Simple Primary Care Screening Tool Predicts Asthma Diagnosis in Preschoolers
The noninvasive, easily administered tool was able to predict at age 3 years children who would be diagnosed with asthma at age 5 years.
Inhaler Education with Teach-to-Goal Methods Improved Technique Among Older Adults with Asthma, COPD
Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.
Continuity of Care for Asthma, COPD Patients Could Improve Survival, Cut Costs
When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.
Patients with Moderate or Severe Asthma Benefit from High-intensity Interval Training, Study Finds
New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.
Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.
Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma
ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.
Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.
NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo
ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.
Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma
ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.
Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.
Adults with Asthma Found at Higher Risk for Obesity in International Study
The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.
Pulmonary Rehab Improves Lung Function, QOL in Asthma-COPD Overlap Plus Obesity
Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.
Factors Linked to Switching Biologic Treatments in Patients with Severe Asthma
Higher blood eosinophils, younger age, and eosinophilic chronic rhinosinusitis were among factors associated with a switch from initial biologic therapy in a new study.
FDA Approves First Generic of Symbicort Inhaler to Treat Asthma, COPD
The FDA has approved the first generic budesonide and formoterol fumarate dihydrate inhalation aerosol for the treatment of asthma and COPD.
Mepolizumab Clinically Effective Regardless of Type 2 Biomarker Status in Patients with Severe Asthma, Suggests Real-world Data
AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.
Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities
Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.
American Academy of Asthma, Allergy & Immunology 2022 News Highlights
AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.
Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis
AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.